The present invention relates to benzodiazepine derivatives, compositions containing therapeutically effective amounts of benzodiazepine derivatives, and methods for using these derivatives or compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of an α5-containing GABA receptor agonist (e.g., a positive allosteric modulator of an α5-containing GABA receptor), as described herein, for the treatment of cognitive impairment associated with disorders of the central nervous system (CNS) in an object in need of such treatment or with a risk of development, including, but not limited to, objects that have or are at risk of development of age-related cognitive impairment, moderate cognitive impairment (AMI), amnestic ACI (aUI), age-related memory impairment (GNP), age-related cognitive decline (ASCF), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS) associated with the treatment of cancer of cognitive impairment, mental retardation, Parkins disease (PD), autism spectrum disorders, fragile X-chromosome syndrome, Re syndrome TTA, compulsive behavior and drug addiction. It also relates to the use of an α5-containing GABA receptor agonist (e.g., a positive allosteric modulator of an α5-containing GABA receptor), as described herein, for the treatment of brain cancer (including brain tumors, for example medulloblastomas) and related cognitive impairment.Настоящее изобретение относится к производным бензодиазепина, композициям, содержащим терапевтически эффективные количества производных бензодиазепина, и способам применения данных производных или композиций для лечения когнитивного нарушения, связанного с нарушениями центральной нервной системы (ЦНС). В частности, оно относится к применению агониста α5-содержащего ГАМКА-рецептора (например, положительного аллостерического модулятора α5
